Previous Close | 4.2700 |
Open | 4.2300 |
Bid | 4.0100 x 100 |
Ask | 4.3000 x 100 |
Day's Range | 4.0500 - 4.2500 |
52 Week Range | 1.2800 - 5.5100 |
Volume | |
Avg. Volume | 222,567 |
Market Cap | 270.291M |
Beta (5Y Monthly) | 1.30 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.3000 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for IPSC
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. “We are fortunate to have Tim and Paul join us at this key st
Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET. A replay of the event will be available on the “Eve